Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

INVESTIGATIONAL ZORYVE (ROFLUMILAST) CREAM 0.05% WAS WELL TOLERATED WITH SAFETY FINDINGS CONSISTENT WITH PRIOR PEDIATRIC EXPERIENCE IN THE INTEGUMENT PROGRAM ZORYVE CREAM IMPROVED SIGNS AND SYMPTOMS OF MILD TO MODERATE ATOPIC DERMATITIS IN INFANTS AGED 3 MONTHS TO LESS THAN 24 MONTHS OVER FOUR WEEKS CAREGIVERS REPORTED RAPID IMPROVEMENT IN ITCH IN AS LITTLE AS 10 MINUTES IN NEARLY HALF OF INFANTS RESULTS FROM ADDITIONAL STUDIES ACROSS THE ZORYVE PORTFOLIO BEING PRESENTED IN THREE POSTER PRESENTATIONS WESTLAKE VILLAGE, CALIF. AND DENVER, MARCH 28, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED NEW DATA FROM THE INTEGUMENT-INFANT PHASE 2 TRIAL DEMONSTRATING THAT ZORYVE (ROFLUMILAST) CREAM 0.05% REDUCED SIGNS AND SYMPTOMS OF ATOPIC DERMATITIS, THE MOST COMMON FORM OF ECZEMA, IN INFANTS AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS.

ARCUTIS PRESENTS NEW PHASE 2 RESULTS IN INFANTS WITH ATOPIC DERMATITIS IN LATE-BREAKING SESSION TODAY AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING

WESTLAKE VILLAGE, CALIF., AND DENVER, MARCH 18, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT IT WILL PRESENT NEW DATA FROM ITS CLINICAL DEVELOPMENT PROGRAM AND MARKETED ZORYVE (ROFLUMILAST) PORTFOLIO DURING THE 2026 AMERICAN ACADEMY OF DERMATOLOGY (AAD) ANNUAL MEETINGTAKING PLACE MARCH 27-31 IN DENVER.

ARCUTIS TO PRESENT NEW CLINICAL DATA IN A LATE-BREAKING PODIUM PRESENTATION AND SCIENTIFIC POSTERS AT THE 2026 AMERICAN ACADEMY OF DERMATOLOGY ANNUAL MEETING

ZORYVE CREAM 0.05% WAS SAFE AND WELL-TOLERATED, WITH EFFICACY THAT WAS MAINTAINED AND IMPROVED OVER TIME UP TO 56 WEEKS OF TREATMENT CHILDREN AGES 2-5 WHO ACHIEVED DISEASE CLEARANCE AND WHO SWITCHED TO PROACTIVE TWICE-WEEKLY APPLICATION SUSTAINED DISEASE CONTROL FOR A MEDIAN DURATION OF ~8 MONTHS THESE RESULTS FURTHER SUPPORT THE COMPANY'S FOCUS ON EXPANDING OPTIONS FOR PEDIATRIC POPULATIONS WESTLAKE VILLAGE, CALIF., MARCH 10, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT PEDIATRIC DERMATOLOGY PUBLISHED DATA FROM THE PHASE 3 OPEN-LABEL EXTENSION (INTEGUMENT-OLE) STUDY EVALUATING ONCE-DAILY ZORYVE (ROFLUMILAST) CREAM 0.05% IN CHILDREN AGED 2 TO 5 YEARS WITH MILD-TO-MODERATE ATOPIC DERMATITIS.

ARCUTIS ANNOUNCES PUBLICATION OF POSITIVE LONG-TERM SAFETY AND EFFICACY DATA WITH ZORYVE (ROFLUMILAST) CREAM 0.05% FOR TREATMENT OF MILD-TO-MODERATE ATOPIC DERMATITIS IN CHILDREN AGES 25 INPEDIATRIC DERMATOLOGY

WESTLAKE VILLAGE, CALIF., MARCH 05, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THE PROMOTION OF MAS MATSUDA, JD, CURRENTLY SENIOR VICE PRESIDENT AND GENERAL COUNSEL, TO EXECUTIVE VICE PRESIDENT, CHIEF LEGAL OFFICER, AND CORPORATE SECRETARY.

ARCUTIS ANNOUNCES PROMOTION OF MAS MATSUDA TO EXECUTIVE VICE PRESIDENT AND CHIEF LEGAL OFFICER TO SUPPORT NEXT PHASE OF GROWTH

PHASE 1A/1B, FIRST-IN-HUMAN STUDY TO EVALUATE SAFETY AND TOLERABILITY FOR INVESTIGATIONAL ARQ-234 IN HEALTHY VOLUNTEERS AND ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS ARQ-234 IS A POTENT FUSION-PROTEIN AGONIST OF THE CD200 RECEPTOR (CD200R), AN IMMUNE-REGULATORY CHECKPOINT INVOLVED IN MAINTAINING IMMUNE BALANCE WESTLAKE VILLAGE, CALIF., MARCH 03, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT THE FIRST PARTICIPANT HAS BEEN ENROLLED IN A PHASE 1A/1B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY, ARQ-234-131, EVALUATING THE SAFETY AND TOLERABILITY OF ARQ-234.

ARCUTIS BEGINS ENROLLING PHASE 1A/1B STUDY EVALUATING ARQ-234, A CD200R AGONIST, IN HEALTHY VOLUNTEERS AND ADULTS WITH ATOPIC DERMATITIS

WESTLAKE VILLAGE, CALIF., FEB. 27, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT ARCUTIS MANAGEMENT WILL PRESENT AT THE TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE, TAKING PLACE MARCH 2-4, 2026, IN BOSTON.

ARCUTIS MANAGEMENT TO PRESENT AT TD COWEN'S 46TH ANNUAL HEALTH CARE CONFERENCE

Q4 2025 NET PRODUCT REVENUE FOR ZORYVE (ROFLUMILAST) WAS $127.5 MILLION, AN 84% INCREASE COMPARED TO Q4 2024, AND A 29% INCREASE COMPARED TO Q3 2025 FULL YEAR 2025 NET PRODUCT REVENUE FOR ZORYVE WAS $372.1 MILLION, AN INCREASE OF 123% OVER THE PRIOR YEAR REPORTED POSITIVE TOPLINE DATA FOR THE INTEGUMENT-INFANT PHASE 2 TRIAL OF ZORYVE CREAM 0.05% IN CHILDREN AGES 3 TO 24 MONTHS WITH MILD TO MODERATE ATOPIC DERMATITIS, WITH A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) SUBMISSION EXPECTED IN Q2 2026 ANNOUNCED EXPANSION OF ITS DERMATOLOGY SALES FORCE AND, SEPARATELY, THE INITIATION OF A TARGETED ARCUTIS COMMERCIALIZATION EFFORT FOR PRIMARY CARE AND PEDIATRIC HEALTH CARE PROVIDERS PRODUCED POSITIVE OPERATING CASH FLOW IN Q4 2025 AND ANTICIPATES MAINTAINING POSITIVE OPERATING CASH FLOW ON A QUARTERLY BASIS GOING FORWARD COMPANY RAISED 2026 FULL YEAR NET PRODUCT SALES GUIDANCE TO $480 MILLION  $495 MILLION WESTLAKE VILLAGE, CALIF., FEB. 25, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED DECEMBER 31, 2025, AND PROVIDED A BUSINESS UPDATE.

ARCUTIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

MAX HOMA SHARES HIS JOURNEY WITH SEBORRHEIC DERMATITIS TO ENCOURAGE OTHERS TO TAKE CONTROL OF THEIR SYMPTOMS ZORYVE (ROFLUMILAST) FOAM 0.3% IS A ONCE-DAILY, STEROID-FREE, LEAVE-IN TOPICAL FOAM UNIQUELY FORMULATED TO TREAT THE ITCHING, REDNESS, AND FLAKING OF SEBORRHEIC DERMATITIS ANYWHERE IT APPEARS, INCLUDING HAIR-BEARING AREAS 10 MILLION AMERICANS LIVE WITH SEBORRHEIC DERMATITIS, A CHRONIC INFLAMMATORY SKIN DISEASE THAT OCCURS MOST OFTEN ON AREAS WITH OIL-PRODUCING GLANDS, INCLUDING THE FACE AND SCALP WESTLAKE VILLAGE, CALIF., FEB. 24, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC.(NASDAQ:ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED THAT SIX-TIME PGA TOUR WINNER MAX HOMA HAS JOINED THE COMPANY'S FREE TO BE ME AWARENESS CAMPAIGN TO HELP ENCOURAGE THE MILLIONS OF AMERICANS LIVING WITH SEBORRHEIC DERMATITIS (SEB DERM) TO SPEAK WITH THEIR HEALTHCARE PROVIDERS ABOUT LONG-TERM TREATMENT OPTIONS.

PROFESSIONAL GOLFER MAX HOMA JOINS ARCUTIS'FREE TO BE ME CAMPAIGN, URGING INDIVIDUALS WITH SEBORRHEIC DERMATITIS TO TEE UP A CONVERSATION WITH THEIR HEALTHCARE PROVIDER ABOUT LONG-TERM TREATMENTS

WESTLAKE VILLAGE, CALIF., FEB. 05, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY REPORTED THE GRANT OF AN AGGREGATE OF 94,000 RESTRICTED STOCK UNITS OF ARCUTIS' COMMON STOCK TO 12 NEWLY HIRED EMPLOYEES. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF ARCUTIS' BOARD OF DIRECTORS AND GRANTED UNDER THE ARCUTIS BIOTHERAPEUTICS, INC. 2022 INDUCEMENT PLAN, WITH A GRANT DATE OF FEBRUARY 2, 2026, AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH ARCUTIS, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ARCUTIS BIOTHERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

WESTLAKE VILLAGE, CALIF., FEB. 02, 2026 (GLOBE NEWSWIRE) -- ARCUTIS BIOTHERAPEUTICS, INC. (NASDAQ: ARQT), A COMMERCIAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEANINGFUL INNOVATIONS IN IMMUNO-DERMATOLOGY, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE INTEGUMENT-INFANT PHASE 2 STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF ZORYVE (ROFLUMILAST) CREAM 0.05% IN INFANTS AGED 3 MONTHS TO LESS THAN 24 MONTHS WITH ATOPIC DERMATITIS. ZORYVE CREAM, A HIGHLY SELECTIVE AND POTENT TOPICAL PHOSPHODIESTERASE 4 (PDE4) INHIBITOR, WAS WELL TOLERATED WITH A SAFETY PROFILE CONSISTENT WITH PREVIOUS ZORYVE CLINICAL TRIALS. OVERALL, THE INCIDENCE OF ADVERSE EVENTS WAS LOW, WITH ALL BEING MILD TO MODERATE IN SEVERITY. ZORYVE CREAM IMPROVED THE SEVERITY OF DISEASE AND REDUCED THE AREA OF SKIN AFFECTED BY ATOPIC DERMATITIS, WITH 58% OF PARTICIPANTS ACHIEVING EASI-75 AT WEEK 4.

ARCUTIS ANNOUNCES POSITIVE TOPLINE RESULTS FOR INTEGUMENT-INFANT PHASE 2 TRIAL OF ZORYVE (ROFLUMILAST) CREAM 0.05% IN INFANTS WITH MILD TO MODERATE ATOPIC DERMATITIS

Arcutis Biotherapeutics, Inc.

ARQT

Price

Financial Reports

No items found.

Press Releases

Arcutis Biotherapeutics, Inc.

ARQT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ARQT